Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir

Summary

This is a multicenter, nonrandomized, open-label, parallel controlled Phase I clinical study to evaluate the Pharmacokinetics, Safety and Tolerability of SIM0417 combined with ritonavir after a single dose in subjects with mild and moderate renal impairment, moderate hepatic impairment, normal renal function, and normal hepatic function. It is divided into Part A (subjects with mild/moderate renal impairment and subjects with normal renal function) and Part B (subjects with moderate hepatic impairment and subjects with normal hepatic function).

Timeline

Start

2023-03-01

Primary completion

2023-12-01

Completion

2023-12-31

Drugs

Indications